Q-omics provides the consensus-scored MAS1LP1 profile across patient tissues and cancer cell-line models. MAS1LP1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MAS1LP1 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, MAS1LP1 RNA expression shows 6,968 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, COAD, and STAD as cancer lineages where MAS1LP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAS1LP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAS1LP1 survival associations across molecular data types. MAS1LP1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAS1LP1 RNA expression–survival associations across cancer types. High MAS1LP1 expression shows unfavorable associations in THCA, COAD and BLCA, but favorable associations in ESCA, LIHC and SKCM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MAS1LP1 RNA expression.
This table summarizes MAS1LP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAS1LP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAS1LP1 shows lower tumor expression in COAD, BLCA, LUSC, LUAD and STAD and higher tumor expression in UCEC. The COAD box plot shows higher MAS1LP1 RNA expression in normal versus tumor tissue (log2 FC = −0.181, t-test p < 0.001).
This table shows molecular features associated with MAS1LP1 in patient tissues and cancer cell lines. In patient samples, MAS1LP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
